• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

7.160 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanda Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections ↗
March 03, 2026
According to Vanda, the FDA has not granted such a hearing in the context of drug approvals for potentially over 40 years. 
Via Stocktwits
News headline image
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder ↗
February 25, 2026
The company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder. 
Via Stocktwits
In today's session, these stocks are experiencing unusual volume. ↗
February 24, 2026
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
February 23, 2026
Via Chartmill
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? ↗
February 12, 2026
Via Stocktwits
Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Stock Plummets 9.8% After Mixed Q4 2025 Earnings Report ↗
February 11, 2026
Via Chartmill
Vanda Stock Drop 10% Premarket After FDA Rejects Jet Lag Drug Application ↗
January 08, 2026
Via Stocktwits
VNDA Stock On Track To Open At Three-Year High – FDA Clears First New Motion Sickness Drug In Decades ↗
December 31, 2025
Via Stocktwits
Here are the top movers in Monday's session. ↗
February 23, 2026
Via Chartmill
These stocks are gapping in today's session ↗
February 23, 2026
Via Chartmill
These stocks are moving in today's pre-market session ↗
February 23, 2026
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
February 23, 2026
Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
Vanda’s FDA Moment: A High-Stakes Bet That Could Redefine The Stock ↗
December 29, 2025
Via Stocktwits
News headline image
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? ↗
February 22, 2026
Vanda said it expects Bysanti to be available in the market in the third quarter of 2026. 
Via Stocktwits
News headline image
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug ↗
February 20, 2026
This is the second Vanda drug to be approved in the span of a few months, after the approval of Nereus in December. 
Via Stocktwits
News headline image
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia ↗
February 19, 2026
The company said that if approved, Bysanti could be available for sale in the U.S. this year. 
Via Stocktwits
News headline image
Vanda (VNDA) Q4 2025 Earnings Call Transcript ↗
February 11, 2026
Vanda (VNDA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
February 03, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
January 27, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
January 20, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
January 13, 2026
From Pomerantz LLP
Via GlobeNewswire
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
January 08, 2026
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
January 02, 2026
Via Chartmill
News headline image
What&#39;s Going On With Vanda Pharmaceuticals Stock Wednesday? ↗
December 31, 2025
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion. 
Via Benzinga
Here are the top movers in Wednesday's session. ↗
December 31, 2025
Via Chartmill
Top movers analysis in the middle of the day on 2025-12-31: top gainers and losers in today's session. ↗
December 31, 2025
Via Chartmill
The market is filled with gapping stocks in Wednesday's session. ↗
December 31, 2025
Via Chartmill
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
December 31, 2025
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Edge Lower For Final Session Of 2025: Why NVDA, TSLA, VNDA Are On Traders' Radar Today ↗
December 31, 2025
Investors head into the final trading session of 2025 with caution. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
December 29, 2025
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap